Today: 22 October 2025
Subscribe
Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins
 ·  ·  ·  · 

Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

by
22 October 2025
  • Huge earnings beat: Q3 sales jumped 20.3% YoY to $5.065 B, beating forecasts [1] [2]. Adjusted EPS was $0.75 (vs. ~$0.72 consensus) [3] [4].
  • Guidance lifted: The company now expects full-year 2025 adjusted EPS of about $3.02–$3.04, above prior consensus [5] [6]. Q4 EPS is guided to $0.77–$0.79, also above analysts’ $0.76 estimate [7].
  • Stock surge: BSX shares popped roughly 4% in pre-market trading on Oct. 22 after hours on the report [8]. As of Oct 22, Boston Scientific trades near $100 per share [9] (about 13% above its 52-week low), not far from its September peak (~$109 [10]).
  • Strong demand: Growth was broad-based – U.S. sales jumped ~27% and cardiovascular devices (like stents and catheters) led with +22.4% sales growth [11]. MedSurg products also grew ~16%.
  • Analyst optimism: Wall Street remains bullish. MarketBeat notes a consensus “Buy” rating on BSX (24 of 26 analysts are bullish) [12]. The average 12-month price target is ~$121 (about 22% upside) [13]. Needham’s Mike Matson recently reiterated a Buy with a $121 target [14], and Gurufocus reports the mean analyst target near $124 [15].
  • New product wins: This quarter included several regulatory and R&D milestones. The FDA and Japanese PMDA approved expanded labeling for its FARAPULSE heart‐ablation system (now cleared for persistent atrial fibrillation) [16] [17]. Boston Scientific also began a key drug-coated balloon trial (AGENT DCB), published positive deep‐brain stimulation (Parkinson’s) results, and announced acquisitions of EluPro and Nalu medical device technologies [18].

Boston Scientific’s Q3 report blew past expectations. Marlborough, MA-based Boston Scientific (NYSE:BSX) posted reported net income of $755 M ($0.51/share GAAP) and adjusted EPS of $0.75 [19] [20], topping the $0.71–$0.72 analysts’ forecast. CEO Mike Mahoney called it “another exceptional quarter of strong performance” [21], fueled by robust growth across all businesses. Total sales were $5.065 B, up 20.3% from a year ago [22]. Importantly, organic (same-currency) revenue grew 15.3%, well above the 12–14% guidance range. U.S. revenues surged ~27% in Q3 [23], reflecting strong demand for its interventional cardiology and MedSurg devices.

Analysts highlighted that every major segment beat. The cardiovascular division – encompassing stents, catheters and related products – jumped +22.4% [24]. MedSurg (including orthopedic and neuromodulation products) grew +16.4%. Even on a GAAP basis, earnings rose sharply: net income was $755 M (vs. $469 M a year ago) [25]. Management now expects full-year revenue growth of roughly 20% (15.5% organic) [26] and lifted its EPS outlook. For 2025 Mahoney forecasts about $3.02–$3.04 adjusted EPS, above the ~2.98 Wall Street estimate [27] [28]. “We are well-positioned for differentiated growth,” he noted [29], pointing to new products and strategic initiatives on the way.

Market optimism at a glance: Roughly 85% of S&P 500 companies have beaten earnings forecasts this quarter [30], helping pull major indexes near record highs despite high valuations. The stock market reaction was enthusiastic: BSX shares jumped ~4% on the earnings news [31]. TradingView shows BSX around $99.90 on Oct 22 [32], up about 5% in the past week and 13% year-to-date. That still leaves room before its Sept. 9 high of ~$109.50 [33]. Investors have bid up Boston Scientific on the solid results and upbeat guidance.

Market analysts broadly recommend buying BSX. MarketBeat reports 26 covering analysts (essentially all ‘Buy’ or better [34]) with an average 12-month target near $121.6 [35]. GuruFocus finds a similar picture: the current consensus price target is about $124.2 (high of $140, low $101) [36], roughly +26% from the October price. Needham’s Mike Matson recently reiterated his Buy rating (PT $121) [37]. These forecasts assume Boston Scientific continues its strong growth trajectory. Even so, some analysts note valuations are rich: Simply Wall St’s discounted cash flow model pegs fair value near $79, implying the stock is ~25% overvalued today [38]. By traditional metrics, BSX trades around 59× forward P/E versus ~29× for the medtech industry (implying a premium for its growth) [39]. That said, many bullish “narratives” – such as rapid growth in advanced therapies or Asia-Pacific expansion – drive far higher targets (up to ~$140) in some models [40].

Beyond the numbers, Boston Scientific’s business momentum looks strong. The company is benefiting from an aging population and expanding use of minimally invasive therapies (stents, catheters, implants, neurostimulators, etc.). For example, the FARAPULSE pulsed‑field ablation system (a newer treatment for atrial fibrillation) gained approval in the U.S. this summer [41] and in Japan this quarter [42], opening large new markets. The firm also acquired EluPro antibiotic envelope technology (to reduce cardiac implant infections) and agreed to buy Nalu Medical’s nerve‑stimulator system for chronic pain [43]. Those strategic moves add to Boston Scientific’s pipeline of revenue drivers.

Broader market conditions are helping too. TechStock² reports that 85% of S&P 500 firms beat Q3 estimates – the best rate in four years [44] – giving investors confidence. Expectations that the Fed will soon cut interest rates (analysts predict two quarter-point cuts by year-end [45]) also support higher-growth stocks. Even in healthcare, pockets of strength are lifting peers: UnitedHealth and Eli Lilly have hit multi-year highs, while medtech giants get attention amid deal activity. (A recent $18B buyout of Hologic highlights how private equity is targeting medtech, “boosting valuations for peers” like Boston Scientific [46].)

Overall, Boston Scientific’s recent news – stellar earnings, raised guidance, and product approvals – paints an optimistic picture for investors. The stock’s current price (~$100) reflects this momentum, but it still trades below the highest Wall Street targets. With a consensus of analysts on the buy-side [47] [48] and a roughly 20–25% median upside predicted, BSX remains in many portfolios’ favor. That said, valuation appears lofty by some measures, so future gains may depend on the company delivering on its growth drivers and successfully integrating its acquisitions.

Sources: Boston Scientific Q3 press release [49] [50]; Associated Press/TU Times Union [51]; Investing.com summary [52] [53]; market data (TradingView) [54]; TechStock² analysis [55] [56]; MarketBeat analyst consensus [57]; GuruFocus news [58] [59]; Simply Wall St valuation report [60] [61] [62]; company press and PR newswire [63] (with additional market context from Reuters/Bloomberg via TechStock² [64] [65]).

Best Healthcare Stock to Buy: Boston Scientific (BSX) Stock Analysis Q2 2025
Watch this video on YouTube.

References

1. www.prnewswire.com, 2. www.chartmill.com, 3. www.prnewswire.com, 4. www.chartmill.com, 5. www.investing.com, 6. www.marketscreener.com, 7. www.investing.com, 8. www.investing.com, 9. www.tradingview.com, 10. www.tradingview.com, 11. www.investing.com, 12. www.marketbeat.com, 13. www.marketbeat.com, 14. www.gurufocus.com, 15. www.gurufocus.com, 16. www.prnewswire.com, 17. www.prnewswire.com, 18. www.marketscreener.com, 19. www.timesunion.com, 20. www.chartmill.com, 21. www.prnewswire.com, 22. www.prnewswire.com, 23. www.investing.com, 24. www.investing.com, 25. www.chartmill.com, 26. www.marketscreener.com, 27. www.investing.com, 28. www.marketscreener.com, 29. www.prnewswire.com, 30. ts2.tech, 31. www.investing.com, 32. www.tradingview.com, 33. www.tradingview.com, 34. www.marketbeat.com, 35. www.marketbeat.com, 36. www.gurufocus.com, 37. www.gurufocus.com, 38. simplywall.st, 39. simplywall.st, 40. simplywall.st, 41. www.prnewswire.com, 42. www.marketscreener.com, 43. www.marketscreener.com, 44. ts2.tech, 45. ts2.tech, 46. ts2.tech, 47. www.marketbeat.com, 48. www.gurufocus.com, 49. www.prnewswire.com, 50. www.prnewswire.com, 51. www.timesunion.com, 52. www.investing.com, 53. www.investing.com, 54. www.tradingview.com, 55. ts2.tech, 56. ts2.tech, 57. www.marketbeat.com, 58. www.gurufocus.com, 59. www.gurufocus.com, 60. simplywall.st, 61. simplywall.st, 62. simplywall.st, 63. www.marketscreener.com, 64. ts2.tech, 65. ts2.tech

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

  1. Verizon Stock Takes a Hit: Analyst Downgrade and CEO Shake-Up Rattle Investors
  2. Nuburu Stock Soars on New Defense Deals – Price, News, and Expert Analysis
  3. AI Buzz Lifts Pegasystems Stock – Pega Shares Soar on Strong Q3 Results and New Platform Launch
  4. Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Related Articles

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry
Previous Story

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

VSee Health (VSEE) Stock Skyrockets 75% on $10M Hospital Teleradiology Contract
Next Story

VSee Health (VSEE) Stock Skyrockets 75% on $10M Hospital Teleradiology Contract

Stock Market Today

  • SharkNinja Rally Looks Set to Continue on Macro Tailwinds and Earnings Beat
    October 22, 2025, 11:26 AM EDT. SharkNinja Inc. (SN) is catching upside momentum as macro conditions improve for discretionary retailers. With consumer spending firming, Fed rate cuts and lower inflation expectations, a retail rebound could lift demand for home appliances. Goldman Sachs' bullish view on the sector backs SharkNinja's setup, while easing short-seller pressure and a 5.3% weekly rally point to improving sentiment. The company delivered a Q2 2025 EPS of $0.97, beating consensus by $0.19, underscoring execution strength ahead of rate moves. However, the stock remains sensitive to housing cycles, since permits and new-home demand drive appliance volumes. The 12-month price target sits near $126.71, implying substantial upside from current levels.
  • Klarna (NYSE:KLAR) Valuation Under Scrutiny as Revenue Grows and Shares Fall
    October 22, 2025, 11:24 AM EDT. Klarna Group (NYSE:KLAR) has cooled off, with shares down about 14% in the last month while annual revenue climbs. The market is awaiting clearer path to profitability amid narrowing losses. The stock trades at a 4.6x price-to-sales ratio, well above the US Diversified Financial average and peers, signaling lofty growth expectations baked in by investors. Risks include slower revenue growth or persistent losses if profits don't materialize. A competing view from the SWS DCF model places fair value around $3.23 per share, versus $37.07 current, suggesting possible overvaluation under long-term cash-flow assumptions. The story hinges on sustained revenue expansion and margin improvement to justify the premium.
  • VRT Twin Momentum Rating Signals Strong Interest for Vertiv Holdings (VRT)
    October 22, 2025, 11:22 AM EDT. Validea's guru analysis rates Vertiv Holdings Co (VRT) at the top of its Twin Momentum Investor model, a strategy developed by Dashan Huang. The approach blends fundamental momentum-driven by earnings, ROE/ROA, accruals, cash operating profitability, gross profit to assets, and net payout ratio-with price momentum to target stocks likely to outperform. VRT is categorized as a large-cap growth stock in the Electronic Instr. & Controls industry. The score is 100% based on fundamentals and valuation, with 80%+ signaling interest and 90%+ signaling strong interest. In the dashboard, Fundamental Momentum: PASS; Momentum: PASS; Final Rank: PASS. The analysis highlights the method's historical outperformance when combining fundamental momentum with price momentum, corroborating the stock's current favorable rating.
  • SPOT Momentum signals top pick: Validea's Wesley Gray strategy flags Spotify (SPOT)
    October 22, 2025, 11:20 AM EDT. Validea's Quantitative Momentum Investor model, built on Wesley Gray's framework, ranks Spotify Technology SA (SPOT) at the top among 22 guru strategies. The momentum approach targets stocks with strong, consistent intermediate-term relative performance, and SPOT receives a 100% rating from this strategy-indicating solid fundamentals and valuation. In the SPOT Guru Analysis, momentum is the primary driver, with the stock passing key tests and categorized as a large-cap growth stock in the Business Services industry. A score above 90% typically signals strong interest, and a 100% reading suggests conviction in continued performance. Investors should weigh this momentum signal alongside growth prospects within a diversified portfolio.
  • ABBV Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Signals Modest Interest
    October 22, 2025, 11:18 AM EDT. ABBVIE INC (ABBV) earns the top slot among Validea's 22 guru strategies from the Partha Mohanram P/B Growth Investor model, rating ABBV at 77%. This growth framework favors low book-to-market stocks with sustained growth traits. In ABBV's profile, the model flags PASS for Book/Market, Return on Assets (ROA), Cash Flow from Operations to Assets, Cash Flow from Operations to Assets vs. ROA, ROA variance, and Sales variance, and PASS for Advertising to Assets. It marks Capital Expenditures to Assets and Research & Development to Assets as FAIL. ABBV is categorized as a large-cap growth stock in the Biotechnology & Drugs space. The 77% score suggests some interest from this strategy (scores of 80% or more indicate interest; above 90% strong interest). Overall, notable strengths coexist with key gaps under this framework.
Go toTop